Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds

Blood

Volumn 126, Issue 1, 2015, Pages 50-60

  Lagrue, Kathryn ^a,b   Carisey, Alex ^a   Morgan, David J ^a   Chopra, Rajesh ^c   Davis, Daniel M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD16 ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; THALIDOMIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EC50; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERFERON PRODUCTION; MICROSCOPY; MULTIPLE MYELOMA; NATURAL KILLER CELL; PERIODICITY; PRIORITY JOURNAL; TREATMENT RESPONSE; ACTIN FILAMENT; ANALOGS AND DERIVATIVES; CELL CULTURE; DRUG EFFECTS; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; SECRETION (PROCESS);

ACTIN CYTOSKELETON; ACTINS; CELLS, CULTURED; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGICAL SYNAPSES; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IGG; THALIDOMIDE;

EID: 84937827650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-625004     Document Type: Article

References (43)

1. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-156.
2. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol. 2008;8(9):713-725.
3. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol. 2009;9(8):568-580.
4. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428): 727-729.
5. Culley FJ, Johnson M, Evans JH, et al. Natural killer cell signal integration balances synapse symmetry and migration. PLoS Biol. 2009;7(7): E1000159.
6. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1): 159-166.
7. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood. 2009;114(13):2657-2666.
8. Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol. 1998;230:63-88.
9. Brown AC, Oddos S, Dobbie IM, et al. Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. PLoS Biol. 2011;9(9):e1001152.
10. Rak GD, Mace EM, Banerjee PP, Svitkina T, Orange JS. Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse. PLoS Biol. 2011;9(9):e1001151.
11. Mace EM, Orange JS. Lytic immune synapse function requires filamentous actin deconstruction by Coronin 1A. Proc Natl Acad Sci USA. 2014; 111(18):6708-6713.
12. Lagrue K, Carisey A, Oszmiana A, et al. The central role of the cytoskeleton in mechanisms and functions of the NK cell immune synapse. Immunol Rev. 2013;256(1):203-221.
13. Brown AC, Dobbie IM, Alakoskela JM, Davis I, Davis DM. Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins. Blood. 2012; 120(18):3729-3740.
14. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138(5):563-579.
15. Frohn C, Höppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol. 2002; 119(3):660-664.
16. Osterborg A, Nilsson B, Björkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: Relation to disease activity. Eur J Haematol. 1990;45(3):153-157.
17. Uchida A, Yagita M, Sugiyama H, Hoshino T, Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: Accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer. 1984;34(3):375-381.
18. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-258.
19. Garć?a-Sanz R, González M, Orfa?o A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol. 1996;93(1):81-88.
20. King MA, Radicchi-Mastroianni MA. Natural killer cells and CD561 T cells in the blood of multiple myeloma patients: Analysis by 4-colour flow cytometry. Cytometry. 1996;26(2):121-124.
21. Ogmundsdóttir HM. Natural killer cell activity in patients with multiple myeloma. Cancer Detect Prev. 1988;12(1-6):133-143.
22. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007;24(3):312-317.
23. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53(9):1666-1676.
24. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocytemediated antibody-dependent cellular cytotoxicity of rituximab-treated CD201 tumor cells. Clin Cancer Res. 2008;14(14):4650-4657.
25. Jungkunz-Stier I, Zekl M, Stühmer T, Einsele H, Seggewiss-Bernhardt R. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. Leuk Lymphoma. 2014; 55(1):168-176.
26. Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFb1. Cancer Immunol Immunother. 2013;62(10): 1637-1648.
27. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol. 2005;128(2):192-203.
28. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NKcell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5): 1605-1613.
29. Cartwright AN, Griggs J, Davis DM. The immune synapse clears and excludes molecules above a size threshold. Nat Commun. 2014;5:5479.
30. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013;121(14): 2704-2714.
31. Fiorcari S, Martinelli S, Bulgarelli J, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015; 100(2):253-262.
32. Chauveau A, Aucher A, Eissmann P, Vivier E, Davis DM. Membrane nanotubes facilitate longdistance interactions between natural killer cells and target cells. Proc Natl Acad Sci USA. 2010; 107(12):5545-5550.
33. Gruda R, Brown AC, Grabovsky V, et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood. 2012;120(19):3915-3924.
34. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol. 2012;13(7):716-723.
35. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013; 31(5):584-591.
36. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345-1350.
37. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343(6168):301-305.
38. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
39. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6): 811-821.
40. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421.
41. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: Implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713-4720.
42. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84(9):553-559.
43. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008; 112(13):5180-5189.